THỰC TRẠNG SỬ DỤNG THUỐC TRÊN NGƯỜI BỆNH SUY TIM CÓ PHÂN SUẤT TỐNG MÁU GIẢM TẠI BỆNH VIỆN ĐA KHOA THÀNH PHỐ CẦN THƠ NĂM 2023

Abstract

Background: Assessing medication usage in patients with HFrEF is essential for managing and optimizing drug use to achieve therapeutic goals, alleviate heart failure symptoms, and reduce hospitalization rates. Objective: To assess the status of medication use in patients with HFrEF and factors associated with medication prescribing practices. Research subjects and methods: A retrospective cross-sectional study was conducted in142 medical records of inpatients diagnosed with HFrEF at Can Tho City General Hospital from January to December 2023. Results: Most cases (97.2%) were prescribed foundational drug classes, with 57.0% receiving a combination of two foundational drug classes. Among foundational therapies, 90.1% of patients received either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB), 72.5% were prescribed a mineralocorticoid receptor antagonist, and 5.6% received a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Age was significantly associated with the prescribing of foundational drug classes and their combinations (p < 0.05). Conclusion: Most patients were prescribed at least one foundational drug class, predominantly a combination of two classes. Age was associated with the choice and combination of foundational therapies.